AmeriPath to Report Financial Results for Fourth Quarter and Year Ended December 31, 2001 - Tuesday, February 19, 2002, Before Market -.Business Editors/Health & Medical Writers RIVIERA BEACH, Fla.--(BUSINESS WIRE)--Feb. 13, 2001 AmeriPath, Inc. (Nasdaq:PATH), one of the nation's leading providers of anatomic pathology services, today announced that it plans to release its complete financial results for the fourth quarter and year ended December 31, 2001 on Tuesday, February 19, 2002, before the market opens. The Company will broadcast its full financial results conference call on Tuesday, February 19, 2002, at 10:00 a.m. Eastern Time over the Internet. The call will by hosted by James C. New, Chairman and Chief Executive Officer, and Gregory A. Marsh, Vice President and Chief Financial Officer. All stockholders and investors are encouraged to participate. This event is available by visiting the Company's website located at http://www.ameripath.com, or through CCBN's Street Events website, located at http://www.streetevents.com. Listeners should go to one of these websites at least fifteen minutes before the call to register and to download and install any necessary audio software. For those unable to attend the live webcast, a replay will be available on these websites for the next 60 days. There is no charge to access the event. A replay of the call will also be available by telephone beginning at 12:00 p.m., February 19th to 12:00 p.m., February 21st. The dial-in number for the telephone replay is 800-633-8284, ID #20353163. AmeriPath is a leading national provider of cancer diagnostics, genomics, and related information services See Information Systems. . During the first nine months of 2001, AmeriPath diagnosed approximately 2.9 million tissue biopsies, and interpreted approximately 1.6 million Pap smears. The company's extensive diagnostics infrastructure includes over 400 pathologists and doctorate-level scientists providing services to 42 independent pathology laboratories, more than 200 hospitals, the Center for Advanced Diagnostics (CAD) and Dermpath Diagnostics, a division of AmeriPath. CAD provides specialized diagnostic testing Diagnostic testing Testing performed to determine if someone is affected with a particular disease. Mentioned in: Von Willebrand Disease and information services including Fluorescence In-Situ Hybridization hybridization /hy·brid·iza·tion/ (hi?brid-i-za´shun) 1. crossbreeding; the act or process of producing hybrids. 2. molecular hybridization 3. (FISH), Flow Cytometry flow cytometry (flōˑ sī·t  ˑ·m , DNA Analysis, Polymerase Chain Reaction polymerase chain reaction (pŏl`ĭmərās') (PCR), laboratory process in which a particular DNA segment from a mixture of DNA chains is rapidly replicated, producing a large, readily analyzed sample of a piece of DNA; the process is (PCR PCR polymerase chain reaction. PCR abbr. polymerase chain reaction Polymerase chain reaction (PCR) ), Molecular Genetics, Cytogenetics cytogenetics /cy·to·ge·net·ics/ (-je-net´iks) the branch of genetics devoted to cellular constituents concerned in heredity, i.e. chromosomes. and HPV HPV human papillomavirus. HPV abbr. human papilloma virus Human papilloma virus (HPV) Typing. AmeriPath has over 60 board-certified dermatopathologists supporting Dermpath Diagnostics, one of the country's leading providers of dermatopathology services in the growing skin diagnostic market. Additionally, AmeriPath provides clinical trial and research development support to firms involved in developing new cancer and genomic diagnostics and therapeutics. Editor's Note: This release is also available at http://www.ameripath.com AmeriPath, Inc. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion